Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Bryan J Burton, Hafsa M Ahmed, Darrian Linton, Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial

Blood (2023) 142 (Supplement 1): 4764.

https://doi.org/10.1182/blood-2023-190871

Published: 2023

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Saulius K. Girnius, Joshua Richter, Kimberly Bogard, Habte A. Yimer, Sudhir Manda, Roger M. Lyons, Stephen J. Noga, Robert M. Rifkin

Blood (2023) 142 (Supplement 1): 6677.

https://doi.org/10.1182/blood-2023-179795

Published: 2023

Journal Articles

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Hans C. Lee, June Li, Heather Lin, Astrid D. Murga, Gabriela M Rodriguez, Mostafa E. Mohamed, Jared Henderson, Sarah Rodriguez, Melody R. Becnel, Donna M. Weber, Swami P. Iyer, Gregory P. Kaufman, Sheeba K. Thomas, Elisabet E. Manasanch, Krina K. Patel, Stephen J. Noga, Michael R. Green, Robert Z. Orlowski, Cara L Haymaker

Blood (2023) 142 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2023-188201

Published: 2023

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Ruemu E. Birhiray, Robert M. Rifkin, Christopher A. Yasenchak, January Fields-Meehan, Roger M. Lyons, Ramalingham Ratnasabapathy, Kimberly Bogard, Kim Tran, Dasha Cherepanov, Stephen J. Noga, Saulius K. Girnius, Stephen J. Noga

Blood (2022) 140 (Supplement 1): 7322–7323.

https://doi.org/10.1182/blood-2022-163071

Published: 2022

Journal Articles

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Robert M. Rifkin, Stephen J. Noga, Saulius K. Girnius, Kimberly Bogard, Sudhir Manda, Habte Yimer, Presley Whidden, Ruemu E. Birhiray, Philip Twumasi-Ankrah, Yikun Guo, Rami Owera, Leon Bernal-Mizrachi, Roger Lyons

Blood (2021) 138 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2021-150094

Published: 2021

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Saulius K. Girnius, MD, Habte A. Yimer, MD, Stephen J. Noga, MDPhD, Sudhir Manda, MD, Roger M. Lyons, MD, Kimberly Bogard, PharmD, Presley Whidden, Dasha Cherepanov, Vickie Lu, PhD, Jack Aiello, EE, MS, BS, Joshua R. Richter, MD, Robert M. Rifkin, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140482

Published: 2020

Journal Articles

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Robert M. Rifkin, MD, Sudhir Manda, MD, Stephen J Noga, MD PhD, Habte A Yimer, MD, Saulius K. Girnius, MD, Ruemu Ejedafeta Birhiray, MD, Christopher A. Yasenchak, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 1882.

https://doi.org/10.1182/blood-2019-124747

Published: 2019

Journal Articles

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Stephen J Noga, MD PhD, Robert M. Rifkin, MD, Sudhir Manda, MD, Ruemu Ejedafeta Birhiray, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 3168.

https://doi.org/10.1182/blood-2019-124784

Published: 2019

Journal Articles

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Robert M Rifkin, MD, Ralph V. Boccia, MD, Suman Kambhampati, MD, Joshua R Richter, MD, Saad Z Usmani, MD, Jack Aiello, EE, MS, BS, Brittany Sickler, BA, BS, Magdalena Schoeneich, MBA, MS, Bingxia Wang, PhD, Susan Zelt, PhD, Presley Whidden, MS, Lawrence E Dollar, PharmD, MS, Liviu Niculescu, MD, Stephen J Noga, MD

Blood (2017) 130 (Supplement 1): 5407.

https://doi.org/10.1182/blood.V130.Suppl_1.5407.5407

Published: 2017

Journal Articles

Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study

Blood (2016) 128 (22): 5681.

https://doi.org/10.1182/blood.V128.22.5681.5681

Published: 2016

Journal Articles

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Shaji Kumar, Ian Flinn, Paul G. Richardson, Parameswaran Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Francesco Turturro, Robert Rifkin, Jeffrey Wolf, Jose Estevam, George Mulligan, Hongliang Shi, Iain J. Webb, S. Vincent Rajkumar

Blood (2012) 119 (19): 4375–4382.

https://doi.org/10.1182/blood-2011-11-395749

Published: 2012

Journal Articles

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph V. Boccia, MD, Stephen J. Noga, MD, PhD, Donald S. Gravenor, MD, Dipti Patel-Donnelly, MD, Robert S. Siegel, MD, Tarun Kewalramani, MD, Edward J. Gorak, DO, MS, Regina A. Swift, RN, Debra Mayo, PharmD, MHA

Blood (2011) 118 (21): 1857.

https://doi.org/10.1182/blood.V118.21.1857.1857

Published: 2011

Journal Articles

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph Boccia, MD, Donald S. Gravenor, MD, Stephen J. Noga, MD, PhD, Robert S Siegel, MD, Regina A. Swift, RN, Michael D Ehrman, MS, Debra Bensen-Kennedy, MD

Blood (2010) 116 (21): 3057.

https://doi.org/10.1182/blood.V116.21.3057.3057

Published: 2010

Journal Articles

Can a Dose-Dense RCHOP-Like Regimen Be Effectively Used In a Community Setting? Results of a Phase II Study Employing Pegylated Liposomal Doxorubicin In Elderly (> age 60) or Cardiac Compromised (LVEF <45%) Patients with Diffuse Large B Cell Lymphoma (DLBCL).

Stephen J. Noga, MD, PhD, Judith Bosley, RN, Pamela Nickoles, RN

Blood (2010) 116 (21): 2797.

https://doi.org/10.1182/blood.V116.21.2797.2797

Published: 2010

Journal Articles

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Kevin Doner, MD, Ian W. Flinn, MD, PhD, Brian K. Ulrich, MD, Stephen J. Noga, MD, PhD, Naveed M. Chowhan, MD, Steven W. Papish, MD, Tallat Mahmood, MD, James A Reeves, MD, Nicholas J. Di Bella, MD, Gerald J. Robbins, MD, Radhakrishnan Ramchandren, MD, Sein Aung, MD, William Lawler, MD, Sudha Parasuraman, MD, Maria M. Corvez, BA, George Mulligan, PhD, John P. Leonard, MD

Blood (2010) 116 (21): 1792.

https://doi.org/10.1182/blood.V116.21.1792.1792

Published: 2010

Journal Articles

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Shaji Kumar, MD, Ian W. Flinn, MD, PhD, Paul G Richardson, MD, Parameswaran Hari, MD, Natalie Scott Callander, MD, Stephen J. Noga, MD, PhD, A. Keith Stewart, MD, Jonathan Glass, MD, FACP, Robert M. Rifkin, MD, Jeffrey L Wolf, MD, Jose Estevam, BS, George Mulligan, PhD, Hongliang Shi, MS, Iain J. Webb, MD, FRCPC, S. Vincent Rajkumar, MD

Blood (2010) 116 (21): 621.

https://doi.org/10.1182/blood.V116.21.621.621

Published: 2010

Journal Articles

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

Shaji Kumar, Ian W. Flinn, Parameswaran N. Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Jonathan Glass, Noopur Raje, Robert M. Rifkin, Hongliang Shi, Iain J. Webb, Paul G. Richardson, S. Vincent Rajkumar

Blood (2009) 114 (22): 127.

https://doi.org/10.1182/blood.V114.22.127.127

Published: 2009

Journal Articles

Pegylated Liposomal Doxobubicin (PLD) Can Be Escalated in a Dose-Dense, 14 Day CDOP-Rituximab Regimen without Affecting Relative Dose Intensity (RDI) in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Who Are Elderly or Have Compromised Cardiac Status.

Stephen J Noga, MD, Ph.D., Judy Bosley, Pamela Nickoles, Pallavi Kumar, Erica Monfred

Blood (2009) 114 (22): 2692.

https://doi.org/10.1182/blood.V114.22.2692.2692

Published: 2009

Journal Articles

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Shaji Kumar, MD, Ian W Flinn, MD, PhD, Stephen J. Noga, MD, PhD, Parameswaran Hari, MD, MS, Robert M. Rifkin, MD, Natalie Scott Callander, MD, Manish Bhandari, MD, Jeffrey Lee Wolf, MD, Cristina Gasparetto, MD, Amrita Krishnan, MD, FACP, Daren D Grosman, MD, PhD, Jonathan Glass, MD, Entezam Asim Sahovic, MD, Hongliang Shi, MS, Iain J. Webb, MD, Paul Richardson, MD, S. Vincent Rajkumar, MD

Blood (2008) 112 (11): 93.

https://doi.org/10.1182/blood.V112.11.93.93

Published: 2008

Journal Articles

Final Results of a Large, Community Based Study Evaluating the Impact of First and Subsequent Cycle Pegfilgrastim on Neutropenic Events in NHL and HD Patients.

Stephen J. Noga, MD, Janak Choksi, MD, Beiying Ding, PhD, Lyndah Dreiling, MD, Howard Ozer, MD

Blood (2006) 108 (11): 1153.

https://doi.org/10.1182/blood.V108.11.1153.1153

Published: 2006

NARROW

A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

Can a Dose-Dense RCHOP-Like Regimen Be Effectively Used In a Community Setting? Results of a Phase II Study Employing Pegylated Liposomal Doxorubicin In Elderly (> age 60) or Cardiac Compromised (LVEF <45%) Patients with Diffuse Large B Cell Lymphoma (DLBCL).

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study

Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.

Pegylated Liposomal Doxobubicin (PLD) Can Be Escalated in a Dose-Dense, 14 Day CDOP-Rituximab Regimen without Affecting Relative Dose Intensity (RDI) in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Who Are Elderly or Have Compromised Cardiac Status.

Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study

Final Results of a Large, Community Based Study Evaluating the Impact of First and Subsequent Cycle Pegfilgrastim on Neutropenic Events in NHL and HD Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only